US4452778A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Synergistic antibacterial compositions and method of treatment of infections caused by multiple antibiotic-resistant organisms
Assignee: Eli Lilly and Co
•
Filing: 1981-12-21
•
Granted: 1984-06-05
•
Expires: 2001-12-21
Abstract
Abstract Antibiotic compositions comprising a 1-oxa β-lactam antibiotic compound of the formula ##STR1## or pharmaceutically acceptable salts thereof and either tobramycin, amikacin or piperacillin exhibit synergistic activity against multiple-antibiotic-resistant organisms. The 1-oxa compound can be used in conjunction with tobramycin, amikacin or piperacillin in a method of treating infections caused by resistant organisms.
Inventors
- 👤 Gordon L. Brier
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 12:48
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/535; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
88 words
A method of treating infections caused by multiple-antibiotic-resistant gram-negative organisms in a warm-blooded animal which comprises administering to said animal a 1-oxa antibiotic compound of the formula ##STR3## or a pharmaceutically acceptable salt thereof in an amount sufficient to produce blood levels of said compound in said animal of at least about 0.02 to about 8 mcg/ml; and administering in conjunction with said 1-oxa antibiotic tobramycin in an amount sufficient to produce blood levels of tobramycin in said animal of between about 0.5 mcg/ml and about 8 mcg/ml.
Claim 2
Independent Claim
88 words
A method of treating infections caused by multiple-antibiotic-resistant gram-negative organisms in a warm-blooded animal which comprises administering to said animal a 1-oxa antibiotic compound of the formula ##STR3## or a pharmaceutically acceptable salt thereof in an amount sufficient to produce blood levels of said compound in said animal of at least about 0.02 to about 8 mcg/ml; and administering in conjunction with said 1-oxa antibiotic tobramycin in an amount sufficient to produce blood levels of tobramycin in said animal of between about 0.5 mcg/ml and about 8 mcg/ml.
Claim 3
Dependent Claim
38 words
The method of claim 1 wherein the multiple-antibiotic-resistant gram-negative organism is selected from the group consisting of Pseudomonas aeruginosa, Serratia marcescens, E. coli, E. cloacae, Klebsiella pneumoniae, Proteus rettgeri, Proteus mirabilis, Proteus vulgaris, Pseudomonas maltophilia and Acinetobacter sp.
Claim 4
Dependent Claim
34 words
The method of claim 1 wherein the multiple-antibiotic-resistant gram-negative organism is selected from the group consisting of Pseudomonas aeruginosa, Serratia marcescens, E. coli, E cloacae, Klebsiella pneumoniae, Proteus rettgeri, Proteus mirabilis and Proteus vulgaris.
Claim 5
Dependent Claim
14 words
A method according to claim 1 for the treatment of infections of Pseudomonas aeruginosa.
Claim 6
Dependent Claim
23 words
The method of claim 1 wherein about 250 mg to about 2 g of the 1-oxa compound is administered in conjunction with tobramycin.
Claim 7
Dependent Claim
26 words
The method of claim 5 wherein said 1-oxa antibiotic blood levels are produced by administering about 250 mg to about 1 g of the 1-oxa compound.
Claim 8
Dependent Claim
27 words
The method of claim 5 wherein said tobramycin blood levels are produced by administering tobramycin at a dose of between about 0.6 mg/kg to about 2 mg/kg.
Claim 9
Dependent Claim
38 words
The method of claim 5 wherein the multiple-antibiotic-resistant gram-negative organism is selected from the group consisting of Pseudomonas aeruginosa, Serratia marcescens, E. coli, E. Cloacae, Klebsiella pneumoniae, Proteus rettgeri, Proteus mirabilis, Proteus vulgaris, Pseudomonas maltophilia and Acinetobacter sp.
Claim 10
Dependent Claim
34 words
The method of claim 5 wherein the multiple-antibiotic-resistant gram-negative organism is selected from the group consisting of Pseudomonas aeruginosa, Serratia marcescens, E. coli, E. Cloacae, Klebsiella pneumoniae, Proteus rettgeri, Proteus mirabilis and Proteus vulgaris.
Claim 11
Dependent Claim
13 words
The method according to claim 9 for treating infections caused by Pseudomonas aeruginosa.
Claim 12
Dependent Claim
37 words
A synergistic antibacterial composition comprising 1 part by weight, as the diacid, of a compound of the formula ##STR4## or a pharmaceutically acceptable salt thereof; and from about 0.02 to about 0.6 parts by weight of tobramycin.
Claim 13
Dependent Claim
37 words
A synergistic antibacterial composition comprising 1 part by weight, as the diacid, of a compound of the formula ##STR4## or a pharmaceutically acceptable salt thereof; and from about 0.02 to about 0.6 parts by weight of tobramycin.
Claim 14
Dependent Claim
30 words
The method for treating infections caused by multiple-antibiotic-resistant gram-negative organisms in a warm-blooded mammal which comprises administering to said mammal an antibiotically effective amount of the composition of claim 11.
References Cited (Backward Citations)
US4138486A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-06-05 | 1987-12-05 | 1988-06-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-06-05 | 1991-12-05 | 1992-06-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-06-05 | 1995-12-05 | 1996-06-05 | $7700.00 | Window Closed / Lapsed |